Samsung Biologics, 97,872 Shares Net Sold by Individuals in Last 5 Days... Stock Price at 827,000 Won (-1.9%)

As of 2:30 PM on the 13th, Samsung Biologics is trading at 827,000 KRW, down 1.9% from the previous day. The trading volume is 267,867 shares, which is about 35.54% of the previous day's volume. Samsung Biologics is known as the bio business holding company of the Samsung Group.

On August 12, analyst Kang Ha-young of KTB Investment & Securities stated, "1) Considering the larger-than-expected scale of the new Plant 4 (180,000L), we have raised the long-term earnings forecast from 2024 onward when Plant 4 is expected to be operational, adjusting the CMO value upward to 56 trillion KRW. 2) The value of Epis shares was slightly lowered to 9 trillion KRW reflecting 2Q earnings. The announcement of a large-scale new plant construction plan indicates a favorable CMO market and confidence in order acquisition. With an expected operating profit CAGR of +37% over the next three years, there appears to be a high possibility of securing blockbuster new drug orders such as for Alzheimer's." He set the target price for Samsung Biologics at 1,000,000 KRW.

Over the past five days, individual investors have net sold 97,872 shares of Samsung Biologics, while foreign investors and institutions have net bought 84,772 shares and 19,866 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.